Developer docs
API playgroundTry for free, no card

Search company profiles

Aelis Farma

Full company profile

uuid0002298

Namestring
Aelis Farma
Legal namestring
AELIS FARMA
Websiteurl
aelisfarma.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Aelis Farma is a Bordeaux-based, clinical-stage biopharmaceutical company founded in 2013 that develops a proprietary new class of small-molecule drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). These compounds selectively inhibit pathological hyperactivity of the CB1 receptor while preserving normal physiological and behavioral brain functions, addressing indications previously considered untreatable due to safety issues with earlier CB1 antagonists. The company's pipeline comprises three tracks: AEF0117, a new molecular entity in Phase 2b for Cannabis Use Disorder with an open FDA IND (trial ongoing in the United States since Q2 2022) supported by NIDA-NIH grants; AEF0217, a second CB1-SSi with completed Phase 1 and ongoing Phase 2B in Europe (188 participants with Down syndrome across France, Italy and Spain, recruitment initiated March 2026, results expected late 2027) supported by EU Horizon H2020 funding and holding a favorable EMA PDCO opinion on its Pediatric Investigation Plan; and a discovery-stage track of additional CB1-SSi candidates aimed at other cannabinoid-dependent and orphan diseases, with recent expansion into obesity and metabolic indications.

The company operates from a Bordeaux headquarters and a Pessac laboratory at the IECB, is listed on Euronext Paris (ticker: AELIS) under the legal form Société anonyme à conseil d'administration, and reports a headcount of 11–50 employees. Aelis Farma is pre-revenue with no commercialized products and no disclosed pricing; its near-term revenue model is built around a €4.5 million July 2024 capital increase that funds operations through Q4 2026, supplemented by non-dilutive grants (including a €458,000 France 2030 award in April 2026). The long-term revenue model is expected to derive from direct commercialization and/or out-licensing agreements with larger pharmaceutical partners following regulatory approval. Leadership is headed by CEO Pier Vincenzo Piazza (one of the scientific founders behind the 2014 Science publication), with Anders Gersel Pedersen as Chairman of the Board.

Short descriptiontext

Aelis Farma is a Bordeaux-based clinical-stage biopharmaceutical company developing CB1-SSi, a proprietary new class of small molecules that selectively inhibit pathological CB1 receptor activity to treat Cannabis Use Disorder (AEF0117) and cognitive deficits in Down syndrome (AEF0217).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPessac, France
HQ citystring
Pessac
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CB1 receptor inhibitors, clinical-stage biopharmaceuticals, neurological disease therapeutics, cannabis use disorder treatment, cognitive deficit therapeutics
Industry1 code
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Clinical-stage Neurology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing proprietary drug candidates targeting the CB1 receptor for brain disorders. Revenue will be generated through product sales upon regulatory approval, with potential for licensing agreements with larger pharmaceutical partners for global commercialization.

webdisclosure.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aelis Farma is a clinical-stage biopharmaceutical company developing a proprietary pipeline of Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), a new pharmacological class of small molecule drugs that selectively inhibit pathological hyperactivity of the CB1 receptor while preserving normal brain functions. Its lead candidates are AEF0117 for Cannabis Use Disorder (in US Phase 2b) and AEF0217 for cognitive deficits associated with Down syndrome (in European Phase 2B), with additional discovery-stage CB1-SSi compounds targeting other cannabinoid-dependent diseases including orphan indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Therapeutic index >13,000 for AEF0117 with no toxic or adverse effects identified to date
+2 more records
Product overview1 text field

Aelis Farma is a Bordeaux-based biopharmaceutical company developing a pipeline of pharmacological inhibitors called CB1-SSi (Signaling Specific inhibitors of the CB1 receptor). This proprietary platform represents a new pharmacological class that selectively inhibits pathological hyperactivity of the CB1 receptor while preserving normal physiological and behavioral functions. The company's pipeline consists of three main drug candidates: AEF0117 (in Phase 2B for cannabis use disorders), AEF0217 (in Phase 2B for cognitive deficits associated with Down syndrome, with potential expansion to Fragile X syndrome and aging-related cognitive impairments), and new CB1-SSi candidates in discovery for other CB1-dependent diseases including orphan diseases.

Product and service3 records
1AEF0117
CategoryDrug Candidate
Description

A new molecular entity (NME) and Signaling Specific inhibitor of the CB1 receptor (CB1-SSi) developed to treat the harmful effects of excessive cannabis use, including Cannabis Use Disorder (CUD). Currently in Phase 2b clinical trial in the United States. High potency in inhibiting THC effects across animal species including primates without side effects on normal behavior, with a therapeutic index >13,000 and favorable ADMET profile.

2AEF0217
CategoryDrug Candidate
Description

Second CB1-SSi drug candidate specifically designed for treatment of cognitive deficits. First therapeutic indication is cognitive deficits in Down syndrome (Trisomy 21), with additional potential in Fragile X syndrome and aging-related cognitive impairments. Phase 2B trial in Europe. High potency in reversing cognitive deficits in validated translational models without behavioral side effects, therapeutic index of 640, favorable ADMET profile.

3New CB1-SSi candidates
CategoryDrug Candidate (Discovery)
Description

New molecular entities with original structure and improved pharmacodynamic properties developed from Aelis Farma's CB1-SSi platform for the treatment of other CB1-dependent diseases, including several orphan diseases. Currently in discovery and preclinical stages.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large-cap CNS biopharma with broad neuroscience pipeline including neurodegenerative and neurodevelopmental programs. Comparable indication space (Down syndrome cognition-relevant research, Fragile X) and licensing-partner archetype for Aelis.

TypeBroad incumbent
Description

Established CNS-focused biopharma with multiple approved neuroscience products. Comparable business model and target indication areas (CNS/neurodevelopmental disorders) though different mechanism.

TypeDirect peer
Description

Clinical-stage biotech developing CB1-targeting small molecules for cannabis use disorder and acute cannabinoid intoxication — directly comparable to Aelis's AEF0117 program and the most relevant head-to-head peer.

TypeBroad incumbent
Description

Mid-cap CNS biopharma with approved neuroscience assets and pipeline in neuropsychiatric and neurodegenerative indications — relevant comparable for commercial-stage CNS biotech trajectory.

TypeBroad incumbent
Description

Commercial-stage CNS biopharma focused on neurological and psychiatric disorders. Comparable end-stage business model as Aelis's assets advance toward commercialization.

TypeDirect peer
Description

Clinical-stage biotech developing cannabinoid receptor-targeting drug candidates. Most directly comparable in terms of mechanism (cannabinoid receptor modulators) and company stage to Aelis.

TypeEmerging player
Description

Late clinical-stage company focused on transdermal cannabinoid therapies for Fragile X syndrome and other CNS conditions — overlapping with Aelis's AEF0217 program in neurodevelopmental cognitive deficits.

TypeBroad incumbent
Description

Specialty pharma with significant CNS/neuroscience portfolio including cannabinoid-derived Epidiolex (via GW Pharmaceuticals acquisition). Larger incumbent with overlapping focus on cannabis-related and CNS disorders.

9Tilray Brands
TypeRegional player
Description

Cannabis-focused pharmaceutical and consumer company with global footprint including cannabinoid-derived drug development. Comparable by virtue of operating in the cannabinoid therapeutics space, though business model is more diversified.

10Therapix Biosciences
TypeEmerging player
Description

Early-stage cannabinoid-based therapeutics developer focused on CNS indications. Similar platform approach using cannabinoid pharmacology, though narrower pipeline than Aelis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aelis Farma

Clinical-stage Neurology Pharmaceuticalsaelisfarma.com

Aelis Farma is a Bordeaux-based clinical-stage biopharmaceutical company developing CB1-SSi, a proprietary new class of small molecules that selectively inhibit pathological CB1 receptor activity to treat Cannabis Use Disorder (AEF0117) and cognitive deficits in Down syndrome (AEF0217).

What Aelis Farma does

Aelis Farma is a Bordeaux-based, clinical-stage biopharmaceutical company founded in 2013 that develops a proprietary new class of small-molecule drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). These compounds selectively inhibit pathological hyperactivity of the CB1 receptor while preserving normal physiological and behavioral brain functions, addressing indications previously considered untreatable due to safety issues with earlier CB1 antagonists. The company's pipeline comprises three tracks: AEF0117, a new molecular entity in Phase 2b for Cannabis Use Disorder with an open FDA IND (trial ongoing in the United States since Q2 2022) supported by NIDA-NIH grants; AEF0217, a second CB1-SSi with completed Phase 1 and ongoing Phase 2B in Europe (188 participants with Down syndrome across France, Italy and Spain, recruitment initiated March 2026, results expected late 2027) supported by EU Horizon H2020 funding and holding a favorable EMA PDCO opinion on its Pediatric Investigation Plan; and a discovery-stage track of additional CB1-SSi candidates aimed at other cannabinoid-dependent and orphan diseases, with recent expansion into obesity and metabolic indications.

The company operates from a Bordeaux headquarters and a Pessac laboratory at the IECB, is listed on Euronext Paris (ticker: AELIS) under the legal form Société anonyme à conseil d'administration, and reports a headcount of 11–50 employees. Aelis Farma is pre-revenue with no commercialized products and no disclosed pricing; its near-term revenue model is built around a €4.5 million July 2024 capital increase that funds operations through Q4 2026, supplemented by non-dilutive grants (including a €458,000 France 2030 award in April 2026). The long-term revenue model is expected to derive from direct commercialization and/or out-licensing agreements with larger pharmaceutical partners following regulatory approval. Leadership is headed by CEO Pier Vincenzo Piazza (one of the scientific founders behind the 2014 Science publication), with Anders Gersel Pedersen as Chairman of the Board.

Aelis Farma firmographics

Firmographics
Name
Aelis Farma
Legal name
AELIS FARMA
Website
https://aelisfarma.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Aelis Farma is a Bordeaux-based clinical-stage biopharmaceutical company developing CB1-SSi, a proprietary new class of small molecules that selectively inhibit pathological CB1 receptor activity to treat Cannabis Use Disorder (AEF0117) and cognitive deficits in Down syndrome (AEF0217).
Ownership category
akta.pro rank

Aelis Farma industry classification

Industry
Product category
Clinical-stage Neurology Pharmaceuticals
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • CB1 receptor inhibitors
  • Clinical-stage biopharmaceuticals
  • Neurological disease therapeutics
  • Cannabis use disorder treatment
  • Cognitive deficit therapeutics

Where Aelis Farma is headquartered

Location

Headquarters

HQ city
Pessac
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Aelis Farma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing proprietary drug candidates targeting the CB1 receptor for brain disorders. Revenue will be generated through product sales upon regulatory approval, with potential for licensing agreements with larger pharmaceutical partners for global commercialization.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Aelis Farma product offering

Product offering

Core offering

Aelis Farma is a clinical-stage biopharmaceutical company developing a proprietary pipeline of Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), a new pharmacological class of small molecule drugs that selectively inhibit pathological hyperactivity of the CB1 receptor while preserving normal brain functions. Its lead candidates are AEF0117 for Cannabis Use Disorder (in US Phase 2b) and AEF0217 for cognitive deficits associated with Down syndrome (in European Phase 2B), with additional discovery-stage CB1-SSi compounds targeting other cannabinoid-dependent diseases including orphan indications.

Product overview

Aelis Farma is a Bordeaux-based biopharmaceutical company developing a pipeline of pharmacological inhibitors called CB1-SSi (Signaling Specific inhibitors of the CB1 receptor). This proprietary platform represents a new pharmacological class that selectively inhibits pathological hyperactivity of the CB1 receptor while preserving normal physiological and behavioral functions. The company's pipeline consists of three main drug candidates: AEF0117 (in Phase 2B for cannabis use disorders), AEF0217 (in Phase 2B for cognitive deficits associated with Down syndrome, with potential expansion to Fragile X syndrome and aging-related cognitive impairments), and new CB1-SSi candidates in discovery for other CB1-dependent diseases including orphan diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • AEF0117 A new molecular entity (NME) and Signaling Specific inhibitor of the CB1 receptor (CB1-SSi) developed to treat the harmful effects of excessive cannabis use, including Cannabis Use Disorder (CUD). Currently in Phase 2b clinical trial in the United States. High potency in inhibiting THC effects across animal species including primates without side effects on normal behavior, with a therapeutic index >13,000 and favorable ADMET profile.
  • AEF0217 Second CB1-SSi drug candidate specifically designed for treatment of cognitive deficits. First therapeutic indication is cognitive deficits in Down syndrome (Trisomy 21), with additional potential in Fragile X syndrome and aging-related cognitive impairments. Phase 2B trial in Europe. High potency in reversing cognitive deficits in validated translational models without behavioral side effects, therapeutic index of 640, favorable ADMET profile.
  • New CB1-SSi candidates New molecular entities with original structure and improved pharmacodynamic properties developed from Aelis Farma's CB1-SSi platform for the treatment of other CB1-dependent diseases, including several orphan diseases. Currently in discovery and preclinical stages.

Quantifiable outcome

  • Therapeutic index >13,000 for AEF0117 with no toxic or adverse effects identified to date
  • +2 more outcomes

Companies that use Aelis Farma

Customer profile

Segments2 records

Ideal customer profiles3 records

Aelis Farma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aelis Farma partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Aelis Farma competitors and assessment

Company assessment

Broad incumbents

  • Biogen: Large-cap CNS biopharma with broad neuroscience pipeline including neurodegenerative and neurodevelopmental programs. Comparable indication space (Down syndrome cognition-relevant research, Fragile X) and licensing-partner archetype for Aelis.
  • Sage Therapeutics: Established CNS-focused biopharma with multiple approved neuroscience products. Comparable business model and target indication areas (CNS/neurodevelopmental disorders) though different mechanism.
  • Intra-Cellular Therapies: Mid-cap CNS biopharma with approved neuroscience assets and pipeline in neuropsychiatric and neurodegenerative indications — relevant comparable for commercial-stage CNS biotech trajectory.
  • ACADIA Pharmaceuticals: Commercial-stage CNS biopharma focused on neurological and psychiatric disorders. Comparable end-stage business model as Aelis's assets advance toward commercialization.
  • Jazz Pharmaceuticals: Specialty pharma with significant CNS/neuroscience portfolio including cannabinoid-derived Epidiolex (via GW Pharmaceuticals acquisition). Larger incumbent with overlapping focus on cannabis-related and CNS disorders.

Direct peers

  • Anebulo Pharmaceuticals: Clinical-stage biotech developing CB1-targeting small molecules for cannabis use disorder and acute cannabinoid intoxication — directly comparable to Aelis's AEF0117 program and the most relevant head-to-head peer.
  • Corbus Pharmaceuticals: Clinical-stage biotech developing cannabinoid receptor-targeting drug candidates. Most directly comparable in terms of mechanism (cannabinoid receptor modulators) and company stage to Aelis.

Emerging players

  • Zynerba Pharmaceuticals: Late clinical-stage company focused on transdermal cannabinoid therapies for Fragile X syndrome and other CNS conditions — overlapping with Aelis's AEF0217 program in neurodevelopmental cognitive deficits.
  • Therapix Biosciences: Early-stage cannabinoid-based therapeutics developer focused on CNS indications. Similar platform approach using cannabinoid pharmacology, though narrower pipeline than Aelis.

Regional players

  • Tilray Brands: Cannabis-focused pharmaceutical and consumer company with global footprint including cannabinoid-derived drug development. Comparable by virtue of operating in the cannabinoid therapeutics space, though business model is more diversified.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Aelis Farma social profiles

Digital presence

Aelis Farma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aelis Farma leadership team

Management profile

Number of profiles

Profiles8 records

Aelis Farma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aelis Farma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aelis Farma

What does Aelis Farma do?

Aelis Farma is a clinical-stage biopharmaceutical company developing a proprietary pipeline of Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), a new pharmacological class of small molecule drugs that selectively inhibit pathological hyperactivity of the CB1 receptor while preserving normal brain functions. Its lead candidates are AEF0117 for Cannabis Use Disorder (in US Phase 2b) and AEF0217 for cognitive deficits associated with Down syndrome (in European Phase 2B), with additional discovery-stage CB1-SSi compounds targeting other cannabinoid-dependent diseases including orphan indications.

Is Aelis Farma a public or private company?

Aelis Farma is a private company. It is classified as public and is currently operating.

When was Aelis Farma founded?

Aelis Farma was founded in 2013. It employs 11 to 50 people.

Where is Aelis Farma based?

Aelis Farma is headquartered in Pessac, France, in the Europe region.

How does Aelis Farma make money?

One revenue line is on record: drug Development and Commercialization.

Who are Aelis Farma's main competitors?

Broad incumbents on record are Biogen, Sage Therapeutics, Intra-Cellular Therapies, ACADIA Pharmaceuticals and Jazz Pharmaceuticals. Direct peers are Anebulo Pharmaceuticals and Corbus Pharmaceuticals. Emerging players are Zynerba Pharmaceuticals and Therapix Biosciences. Tilray Brands is listed as a regional player.

Does Aelis Farma have an API?

No public API is recorded for Aelis Farma.

What industry is Aelis Farma in?

Aelis Farma's product category is Clinical-stage Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAelis Farma Receives a Second Positive Recommendation From the Independent Data Monitoring Committee for Its Phase 2b Study with AEF0217 in People With Down syndromeAelis Farma's Independent Data Monitoring Committee gave a second positive recommendation for its Phase 2b study of AEF0217 in people with Down syndrome, based on safety data from 74 participants. The review found no serious or severe adverse events and recommended continuing the study without modification, with a potential 12-month open-label extension. Results are expected by end of 2027.The future of tradingAelis Farma’s AEF0217 Phase 2b Trial Gets Second Safety Panel Backing to Continue UnchangedAelis Farma received a second independent safety endorsement to continue its Phase 2b AEF0217 trial in Down syndrome without protocol changes. Safety findings from Nov. 16, 2026, showed favorable tolerability with no serious or severe adverse events. The monitoring committee also supported a potential 12-month open-label extension, with clinical results expected by year-end 2027.MorningstarAelis Farma Reports 2026 Half-Year Financial Results and Presents Progress and Development OutlookAelis Farma reported H1 2026 results with revenue of €449,000 and a net loss of €2.4 million, and a cash position of €6.6 million. The company received a positive EMA opinion on AEF0217's pediatric plan and continues recruitment in the Phase 2b study. It expects results before end of 2027 and financial visibility through early 2028.Business Wire BlogAelis Farma Reports 2026 Half-Year Financial Results and Presents Progress and Development OutlookAelis Farma reported H1 2026 results with revenue of €449,000 and a net loss of €2.4 million, holding €6.6 million in cash. The company received a positive EMA opinion on AEF0217's pediatric plan and continues recruitment in its Phase 2b study. It expects first results in Q4 2027 and aims to enter industry partnerships by 2028.MarketScreenerAelis continues development of AEF0217 in Down syndrome, shares riseAelis Farma announced it received a positive recommendation from an independent data monitoring committee to continue its Phase 2b clinical trial for AEF0217 in Down syndrome without modifications. The review found no serious adverse events among 42 randomized participants, with all reported adverse events being mild in intensity and no participant discontinuing due to adverse events. The company's shares rose more than 9% on the Paris Bourse following the announcement, with enrollment progressing as planned toward 188 participants.Investing.comAelis Farma’s Down syndrome trial clears safety review By Investing.comAelis Farma announced that an independent data monitoring committee recommended continuation of its Phase 2b clinical trial evaluating AEF0217 for Down syndrome after reviewing safety data from 42 randomized participants. The committee reported no severe or serious adverse events, with all reported adverse events classified as mild and none considered related to the investigational treatment. The trial is currently 37% enrolled with 65 participants randomized, and the company aims to complete recruitment of all 188 participants by the end of 2026.Investing.comAelis Farma’s Down syndrome trial clears safety review By Investing.comAelis Farma announced that an independent data monitoring committee recommended continuation of its Phase 2b clinical trial evaluating AEF0217 in adults and older adolescents with Down syndrome, after reviewing safety data from 42 randomized participants including 32 who completed at least four weeks of treatment. The committee reported no severe or serious adverse events, with all reported events classified as mild and none considered related to the investigational treatment. The trial has enrolled 65 of its planned 188 participants across clinical centers in France, Spain, and Italy, with recruitment targeted for completion by the end of 2026 and study results expected by the end of 2027.Investing.comAelis Farma’s Down syndrome trial clears safety review By Investing.comAelis Farma announced that an independent data monitoring committee recommended continuation of its Phase 2b clinical trial evaluating AEF0217 in adults and older adolescents with Down syndrome, following a safety review of 42 randomized participants. No severe or serious adverse events were reported, with all adverse events classified as mild and considered unrelated to the investigational treatment. The trial plans to enroll 188 participants across clinical centers in France, Spain, and Italy, with 65 participants currently randomized and results expected by the end of 2027.Investing.comAelis Farma’s Down syndrome trial clears safety review By Investing.comAelis Farma announced that an independent data monitoring committee recommended continuation of its Phase 2b clinical trial evaluating AEF0217 in adults and older adolescents with Down syndrome, following a first safety review of 42 randomized participants. The review found no severe or serious adverse events, with all reported adverse events classified as mild and considered unrelated to the investigational treatment. The trial, enrolling 188 participants across clinical centers in France, Spain, and Italy, has randomized 65 participants so far, with the company targeting completion of recruitment by end of 2026 and study results by end of 2027.MorningstarAelis Farma Receives a Positive Recommendation From the Independent Data Monitoring Committee to Continue the Phase 2b Study of AEF0217 in People With Down Syndrome Without ModificationAelis Farma's Independent Data Monitoring Committee recommended continuing its Phase 2b study of AEF0217 in people with Down syndrome without modification. The review of 42 randomized participants found no severe or serious adverse events, all events were mild and unrelated to treatment. Recruitment is progressing, with 65 of 188 participants randomized, and results expected by end of 2027.